We previously developed TSLPR-targeted CAR T cell immunotherapy (TSLPRCART) and demonstrated robust and sustained activity in vivo in CRLF2-overexpressing (CRLF2+) ALL xenograft models [35]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.